Oct. 9, 2025
| Today’s news and insights for biopharma leaders
The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.
|
Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.
|
The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies.
|
Proactive selection can help avoid costly fixes: The impact of label stock quality on CDMOs and pharmaceutical companies.
|
UPDATED
Expedition Therapeutics, a startup aiming to in-license drugs from China, raised $165 million in the third nine-figure Series A round announced in the last three days.
|
Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.
|
|
Pharma leaders investing millions in events often lack visibility into cross-meeting engagement patterns that could maximize ROI. Explore a data approach that turns attendee insights into advantages in this playbook.
|
|
From Our Library
Playbook
Custom content for WCG
|
Webinar - on demand
Custom content for Endava
|
Infographic
Custom content for Woven Health Collective
|
Trendline
Supported by ELEGEN
| | 
